Could adding veliparib boost chemo for tough blood cancers?

NCT ID NCT03289910

First seen Mar 06, 2026 · Last updated May 01, 2026 · Updated 7 times

Summary

This study tests whether adding the drug veliparib to standard chemotherapy (topotecan and carboplatin) works better than chemo alone for people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults with these cancers that have spread or come back after treatment will take part. The goal is to see if the combination can shrink or control the cancer better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California, 92663, United States

Conditions

Explore the condition pages connected to this study.